专利检索 ap:("Merck Sharp & Dohme Corp.") AND inv:"Wei Zhou" 第 1 页

1.

发明申请
MACROCYCLIC SPIROCARBAMATE DERIVATIVES AS FACTOR XIA INHIBITORS, PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS AND THEIR USE 审中-公开

公开(公告)号：US20180311250A1

公开(公告)日：2018-11-01

申请号：US15771136

申请日：2016-10-24

申请人： MERCK SHARP & DOHME CORP.

发明人： Amjad Ali , Yeon-Hee Lim , Jiayi Xu , Wei Zhou

IPC分类号： A61K31/537 , A61P7/02 , A61P7/04

CPC分类号： C07D519/00 , A61P7/00 , C07D498/10

摘要： The present invention provides a compound of Formula (I) and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds and said stereoisomers, and pharmaceutical compositions thereof, and methods for using said compounds and compositions for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

2.

发明申请
NOVEL COMPOUNDS THAT ARE ERK INHIBITORS 审中-公开

公开(公告)号：US20170320882A1

公开(公告)日：2017-11-09

申请号：US15656176

申请日：2017-07-21

申请人： Merck Sharp & Dohme Corp.

发明人： Jongwon Lim , Xianhai Huang , Ronald D. Ferguson , Wei Zhou , Christopher W. Boyce , Phieng Siliphaivanh , David J. Witter , Milana M. Maletic , Joseph A. Kozlowski , Kevin J. Wilson

IPC分类号： C07D487/04 , C07D471/04 , C07D471/14 , C07D519/00

CPC分类号： C07D487/04 , C07D471/04 , C07D471/14 , C07D519/00

摘要： Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I).

3.

发明申请
PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES 有权
标题翻译：哌嗪取代[1,2,4]三唑[1,5-C]喹唑啉-5-胺化合物，具有A2A拮抗剂性质

公开(公告)号：US20160194330A1

公开(公告)日：2016-07-07

申请号：US14655572

申请日：2013-12-20

申请人： Amjad ALI , Michael Man-Chu LO , Yeon-Hee LIM , Andrew STAMFORD , Rongze KUANG , Paul TEMPEST , Younong YU , Michael BERLIN , Pauline TING , Gang ZHOU , Tao YU , Christopher BOYCE , Joseph Michael KELLY , Jayaram TAGAT , Junying ZHENG , Xianhai HUANG , Wei ZHOU , Jae-Hun KIM , Nicolas ZORN , Dong XIAO , Gioconda V. GALLO , Walter WON , Heping WU , Rajan ANAND , MERCK SHARP & DOHME CORP.

发明人： Amjad Ali , Michael Man-Chu Lo , Yeon-Hee Lim , Andrew Stamford , Rongze Kuang , Paul Tempest , Younong Yu , Michael Berlin , Pauline Ting , Gang Zhou , Tao Yu , Christopher Boyce , Joseph Michael Kelly , Jayaram R. Tagat , Junying Zheng , Xianhai Huang , Wei Zhou , Jae-Hun Kim , Nicolas Zorn , Dong Xiao , Gioconda V. Gallo , Walter Won , Heping Wu , Rajan Anand , Qiaolin Deng

IPC分类号： C07D487/04 , C07D487/18 , C07D487/08 , C07D513/04

CPC分类号： C07D487/04 , C07D487/08 , C07D487/18 , C07D513/04

摘要： Disclosed are compounds of Formula A: (structurally represented) where “RG1”, “RG2a”, “RG4”, “RG5”, “MG1”, “n” and “m” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

摘要翻译： 公开了式A化合物（结构表示），其中“RG1”，“RG2a”，“RG4”，“RG5”，“MG1”，“n”和“m”在本文中定义为哪些化合物是A2A受体的拮抗剂。本文还公开了本文所述的化合物作为A2a受体的拮抗剂的潜在治疗或预防涉及A2A受体的神经障碍和疾病的用途。本文还公开了包含这些化合物的药物组合物和这些药物组合物的用途。

4.

发明申请
NOVEL COMPOUNDS THAT ARE ERK INHIBITORS 有权
标题翻译：新的化合物是ERK抑制剂

公开(公告)号：US20150266895A1

公开(公告)日：2015-09-24

申请号：US14431462

申请日：2013-09-26

申请人： Kevin J. WILSON , David J. WITTER , Phieng SILIPHAIVANH , Kathryn KIPFORD , David SLOMAN , Danielle FALCONE , Brendan O'BOYLE , Umar Faruk MANSOOR , Jongwon LIM , Joey L. METHOT , Christopher BOYCE , Lei CHEN , Matthew H. DANIELS , Salem FEVRIER , Xianhai HUANG , Ravi KURUKULASURIYA , Ling TONG , Wei ZHOU , Joseph KOZLOWSKI , Milana M. MALETIC , Bidhan A. SHINKRE , Jayanth Thiruvellore THATAI , Raman Kumar BAKSHI , Ganesh Babu KARUNAKARAN , MERCK SHARP & DOHME CORP.

发明人： Kevin J. Wilson , David J. Witter , Phieng Siliphaivanh , Kathryn Lipford , David Sloman , Danielle Falcone , Brendan O'Boyle , Umar Faruk Mansoor , Jongwon Lim , Joey L. Methot , Christopher Boyce , Lei Chen , Matthew H. Daniels , Salem Fevrier , Xianhai Huang , Ravi Kurukulasuriya , Ling Tong , Wei Zhou , Joseph Kozlowski , Milana M. Maletic , Bidhan A. Shinkre , Jayanth Thiruvellore Thatai , Raman Kumar Bakshi , Ganesh Babu Karunakaran

IPC分类号： C07D498/18 , A61K31/437 , A61K31/5377 , A61K31/496 , A61K45/06 , A61K31/4375 , C07D498/14 , A61K31/553 , C07D519/00 , C07D471/04 , C07D471/14

CPC分类号： C07D498/18 , A61K31/437 , A61K31/4375 , A61K31/496 , A61K31/5377 , A61K31/553 , A61K45/06 , C07D471/04 , C07D471/14 , C07D471/16 , C07D498/14 , C07D498/16 , C07D519/00 , A61K2300/00

摘要： Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).

摘要翻译： 公开了式（1）的ERK抑制剂及其药学上可接受的盐。还公开了使用式（1）的化合物治疗癌症的方法。

5.

发明授权
Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use 有权

公开(公告)号：US10344039B2

公开(公告)日：2019-07-09

申请号：US15771136

申请日：2016-10-24

申请人： MERCK SHARP & DOHME CORP. , Amjad Ali , Yeon-Hee Lim , Jiayi Xu , Wei Zhou

发明人： Amjad Ali , Yeon-Hee Lim , Jiayi Xu , Wei Zhou

IPC分类号： C07D519/00 , C07D498/10 , A61P7/00

摘要： The present invention provides a compound of Formula (I) and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds and said stereoisomers, and pharmaceutical compositions thereof, and methods for using said compounds and compositions for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

6.

发明授权
Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties 有权

公开(公告)号：US09676780B2

公开(公告)日：2017-06-13

申请号：US14655572

申请日：2013-12-20

申请人： MERCK SHARP & DOHME CORP. , Amjad Ali , Michael Man-Chu Lo , Yeon-Hee Lim , Andrew Stamford , Rongze Kuang , Paul Tempest , Younong Yu , Michael Berlin , Pauline Ting , Gang Zhou , Tao Yu , Christopher Boyce , Joseph Michael Kelly , Jayaram R. Tagat , Junying Zheng , Xianhai Huang , Wei Zhou , Jae-Hun Kim , Nicolas Zorn , Dong Xiao , Gioconda V. Gallo , Walter Won , Heping Wu , Rajan Anand , Qiaolin Deng

发明人： Amjad Ali , Michael Man-Chu Lo , Yeon-Hee Lim , Andrew Stamford , Rongze Kuang , Paul Tempest , Younong Yu , Michael Berlin , Pauline Ting , Gang Zhou , Tao Yu , Christopher Boyce , Joseph Michael Kelly , Jayaram R. Tagat , Junying Zheng , Xianhai Huang , Wei Zhou , Jae-Hun Kim , Nicolas Zorn , Dong Xiao , Gioconda V. Gallo , Walter Won , Heping Wu , Rajan Anand , Qiaolin Deng

IPC分类号： C07D487/04 , A61K31/519 , C07D487/08 , C07D487/18 , C07D513/04

CPC分类号： C07D487/04 , C07D487/08 , C07D487/18 , C07D513/04

摘要： Disclosed are compounds of Formula A: (structurally represented) where “RG1”, “RG2a”, “RG4”, “RG5”, “MG1”, “n” and “m” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

7.

发明申请
SUBSTITUTED ISOQUINOLINES AS CRTH2 RECEPTOR MODULATORS 有权
标题翻译：替代的异喹啉作为CRTH2受体调节剂

公开(公告)号：US20150353498A1

公开(公告)日：2015-12-10

申请号：US14432462

申请日：2013-09-26

申请人： Xianhai HUANG , Anandan PALANI , Ashwin U. RAO , Hongjun ZHANG , Wei ZHOU , MERCK SHARP & DOHME CORP.

发明人： Xianhai Huang , Anandan Palani , Ashwin U. Rao , Hongjun Zhang , Wei Zhou

IPC分类号： C07D217/24 , C07D401/06 , C07D413/14 , A61K31/4725 , C07D413/04 , A61K31/472 , A61K31/496

CPC分类号： C07D217/24 , A61K31/47 , A61K31/4709 , A61K31/472 , A61K31/4725 , A61K31/496 , A61K45/06 , C07D401/06 , C07D401/12 , C07D413/04 , C07D413/14 , A61K2300/00

摘要： The invention provides certain substituted isoquinolines of the Formula (I), and their pharmaceutically acceptable salts and esters. The invention also provides pharmaceutical compositions comprising for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH2 function.

摘要翻译： 本发明提供某些式（I）的取代的异喹啉及其药学上可接受的盐和酯。本发明还提供药物组合物，其包含用于治疗与不受控制或不适当刺激CRTH2功能相关的疾病或病症。

8.

发明申请
NOVEL COMPOUNDS THAT ARE ERK INHIBITORS 审中-公开

公开(公告)号：US20180319804A1

公开(公告)日：2018-11-08

申请号：US16032715

申请日：2018-07-11

申请人： Merck Sharp & Dohme Corp.

发明人： Jongwon Lim , Xianhai Huang , Ronald D. Ferguson , Wei Zhou , Christopher W. Boyce , Phieng Siliphaivanh , David J. Witter , Milana M. Maletic , Joseph A. Kozlowski , Kevin J. Wilson

IPC分类号： C07D487/04 , C07D519/00 , C07D471/04 , C07D471/14

CPC分类号： C07D487/04 , C07D471/04 , C07D471/14 , C07D519/00

摘要： Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I).

9.

发明授权
Substituted isoquinolines as CRTH2 receptor modulators 有权
标题翻译：取代的异喹啉作为CRTH2受体调节剂

公开(公告)号：US09290454B2

公开(公告)日：2016-03-22

申请号：US14432462

申请日：2013-09-26

申请人： Merck Sharp & Dohme Corp.

发明人： Xianhai Huang , Anandan Palani , Ashwin U. Rao , Hongjun Zhang , Wei Zhou

IPC分类号： C07D413/04 , C07D401/06 , C07D217/24 , A61K31/472 , A61K31/496 , A61K31/4725 , C07D413/14

CPC分类号： C07D217/24 , A61K31/47 , A61K31/4709 , A61K31/472 , A61K31/4725 , A61K31/496 , A61K45/06 , C07D401/06 , C07D401/12 , C07D413/04 , C07D413/14 , A61K2300/00

摘要： The invention provides certain substituted isoquinolines of the Formula (I), and their pharmaceutically acceptable salts and esters. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH2 function.

摘要翻译： 本发明提供某些式（I）的取代的异喹啉及其药学上可接受的盐和酯。本发明还提供包含这些化合物的药物组合物，以及使用该化合物治疗与不受控制或不适当刺激CRTH2功能有关的疾病或病症的方法。